Suchergebnisse
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago
Arvinas Q2 Earnings Call Highlights
Key Points
- Interested in Arvinas, Inc.? Here are five stocks we like better.
- Arvinas is shifting resources to early-stage oncology and neurology programs after the FDA approved VEPPANU, the
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas, Inc. (ARVN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates